Cited by 634Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 139 of the 142 references it cites were found in a registry or an index.

Improving cancer immunotherapy through nanotechnology

Goldberg, Michael S.·2019·Nature reviews. Cancer

Open this paper in CoChat — free account

Abstract

The 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a patient's coordinated and adaptive immune system to fight the patient's unique tumour has now been validated robustly in the clinic. Still, the proportion of patients who respond to immunotherapy remains modest (~15% objective response rate across indications), as tumours have multiple means of immune evasion. The immune system is spatiotemporally controlled, so therapies that influence the immune system should be spatiotemporally controlled as well, in order to maximize the therapeutic index. Nanoparticles and biomaterials enable one to program the location, pharmacokinetics and co-delivery of immunomodulatory compounds, eliciting responses that cannot be achieved upon administration of such compounds in solution. The convergence of cancer immunotherapy, nanotechnology, bioengineering and drug delivery is opportune, as each of these fields has matured independently to the point that it can now be used to complement the others substantively and rationally, rather than modestly and empirically. As a result, unmet needs increasingly can be addressed with deductive intention. This Review explores how nanotechnology and related approaches are being applied to augmenting both endogenous leukocytes and adoptively transferred ones by informing specificity, influencing localization and improving function.

Integrity signals

Registry

Crossref · 10.1038/s41568-019-0186-9

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Delivery technologies for cancer immunotherapy
Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,678
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O’Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,355
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,140
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,103
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. A., & Moon, J. J. (2016) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,075
The Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lü, Y., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,029
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Egeren, D. V., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 949
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 907
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 858
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 845
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 824
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
Bartlett, D. W., Su, H. C., Hildebrandt, I. J., Weber, W., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 820
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 801
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010) · Nature Medicine · doi:10.1038/nm.2198 · Cited by 752
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
Shae, D., Becker, K. W., Christov, P. P., Yun, D. S., Lytton‐Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M. C., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 694
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
Lin, J., Izar, B., Wang, S., Yapp, C., Mei, S., Shah, P., Santagata, S., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.31657 · Cited by 685
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 675
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Tang, L., Zheng, Y., Melo, M. B., Mabardi, L., Castaño, A. P., Xie, Y., Li, N., Kudchodkar, S. B., Wong, H. C., Jeng, E. K., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4181 · Cited by 663
Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Tseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 656
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G. M., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K. K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 583
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Lin, J., Fallahi‐Sichani, M., & Sorger, P. K. (2015) · Nature Communications · doi:10.1038/ncomms9390 · Cited by 562
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552
Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy
Kim, J., Li, A. W., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2014) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 546
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 530
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 528
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Beatty, G. L., O’Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.029 · Cited by 516
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 493
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 473
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Mechanical forces in the immune system
Huse, M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.74 · Cited by 452
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy
Krall, J. A., Reinhardt, F., Mercury, O. A., Pattabiraman, D. R., Brooks, M. W., Dougan, M. L., Lambert, A. W., Bierie, B., Ploegh, H. L., Dougan, S. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3464 · Cited by 452
T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01830-8 · Cited by 449
Self-citation
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2014) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 440
Injectable cryogel-based whole-cell cancer vaccines
Bencherif, S. A., Sands, R. W., Ali, O. A., Li, A. W., Lewin, S. A., Braschler, T. M., Shih, T., Verbeke, C. S., Bhatta, D. B., Dranoff, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms8556 · Cited by 423
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 393
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W. D., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 392
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
Cheung, A. S., Zhang, D. K. Y., Koshy, S. T., & Mooney, D. J. (2018) · Nature Biotechnology · doi:10.1038/nbt.4047 · Cited by 384
Efficient Nanovaccine Delivery in Cancer Immunotherapy
Zhu, G., Zhang, F., Ni, Q., Niu, G., & Chen, X. S. (2017) · ACS Nano · doi:10.1021/acsnano.7b00978 · Cited by 371
Eradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 357
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Ribas, A., Medina, T. M., Kummar, S., Amin, A., Kalbasi, A. K., Drabick, J. J., Barve, M. A., Daniels, G. A., Wong, D. J. L., Schmidt, E. V., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0280 · Cited by 341
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 339
SLC19A1 is an importer of the immunotransmitter cGAMP.
Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C., & Li, L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.006 · Cited by 333
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 326
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Park, C. G., Hartl, C., Schmid, D., Carmona, E. M., Kim, H., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 326
Self-citation
Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S. M., Bórquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Huang, B., Abraham, W. D., Zheng, Y., Bustamante-Lopez, S. C., Luo, S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 316
Delivering safer immunotherapies for cancer
Milling, L. E., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 311
Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
Tokatlian, T., Read, B. J., Jones, C. A., Kulp, D. W., Menis, S., Chang, J. Y. H., Steichen, J. M., Kumari, S., Allen, J. D., Dane, E. L., et al. (2018) · Science · doi:10.1126/science.aat9120 · Cited by 307
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 304
Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., Brown, A. E., Triggiano, M. A., Hux, J. A., Pham, C. D., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.005 · Cited by 285
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 281
Self-citation
Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
Harrington, K. J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., & Golan, T. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.015 · Cited by 280
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 267
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Wing, A., Fajardo, C. A., Posey, A. D., Shaw, C. E., Da, T., Young, R. M., Alemany, R., June, C. H., & Guedan, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0314 · Cited by 262
Macroscale biomaterials strategies for local immunomodulation
Dellacherie, M. O., Seo, B. R., & Mooney, D. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0106-3 · Cited by 262
Immunomodulatory spherical nucleic acids
Radovic‐Moreno, A. F., Chernyak, N., Mader, C. C., Nallagatla, S., Kang, R. S., Hao, L., Walker, D., Halo, T. L., Merkel, T. J., Rische, C. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502850112 · Cited by 260
In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice
Ali, O. A., Emerich, D. F., Dranoff, G., & Mooney, D. J. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000359 · Cited by 250
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Zhang, Y., Li, N., Suh, H., & Irvine, D. J. (2017) · Nature Communications · doi:10.1038/s41467-017-02251-3 · Cited by 248
Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells
Sunshine, J. C., Perica, K., Schneck, J. P., & Green, J. J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.050 · Cited by 245
A carbon nanotube–polymer composite for T-cell therapy
Fadel, T. R., Sharp, F. A., Vudattu, N. K., Ragheb, R. R. T., Garyu, J., Kim, D., Hong, E., Li, N., Haller, G. L., Pfefferle, L. D., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.154 · Cited by 243
Magnetic Field-Induced T Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity
Perica, K., Tu, A. A., Richter, A., Bieler, J. G., Edidin, M. A., & Schneck, J. P. (2014) · ACS Nano · doi:10.1021/nn405520d · Cited by 241
A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells
Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D. A., Hong, W., Schallmoser, K., Strunk, D., & Majeti, R. (2016) · Nature Medicine · doi:10.1038/nm.4103 · Cited by 229
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 220
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.029 · Cited by 210
Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Kwong, B., Gai, S. A., Elkhader, J. A., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 199
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
Moffett, H. F., Coon, M. E., Radtke, S., Stephan, S. B., McKnight, L. E., Lambert, A. R., Stoddard, B. L., Kiem, H., & Stephan, M. T. (2017) · Nature Communications · doi:10.1038/s41467-017-00505-8 · Cited by 190
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery
Predina, J. D., Eruslanov, E. B., Judy, B. F., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, E. K., Fridlender, Z. G., Albelda, S. Μ., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211850110 · Cited by 188
Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination
Li, A. V., Moon, J. J., Abraham, W. D., Suh, H., Elkhader, J. A., Seidman, M. A., Yen, M., Im, E., Foley, M. H., Barouch, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006516 · Cited by 187
Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing
Dura, B., Dougan, S. K., Barisa, M., Hoehl, M. M., Lo, C. T., Ploegh, H. L., & Joel Voldman, B. (2015) · Nature Communications · doi:10.1038/ncomms6940 · Cited by 186
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination
Nembrini, C., Stano, A., Dane, K. Y., Ballester, M. C., van der Vlies, A. J., Marsland, B. J., Swartz, M. A., & Hubbell, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104264108 · Cited by 185
Synthetic immune niches for cancer immunotherapy
Weiden, J., Tel, J., & Figdor, C. G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.89 · Cited by 179
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 174
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer
Bobisse, S., Genolet, R., Roberti, A., Tanyi, J. L., Racle, J., Stevenson, B. J., Iseli, C., Michel, A., Bitoux, M. L., Guillaume, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03301-0 · Cited by 165
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 156
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
Sommer, C., Boldajipour, B. A., Kuo, T. C., Bentley, T., Sutton, J. E., Chen, A., Geng, T., Dong, H., Galetto, R., Valton, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.001 · Cited by 156
Translating nucleic acid-sensing pathways into therapies
Junt, T., & Barchet, W. (2015) · Nature reviews. Immunology · doi:10.1038/nri3875 · Cited by 153
Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation
Hickey, J. W., Vicente, F. P., Howard, G. P., Mao, H., & Schneck, J. P. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03734 · Cited by 151
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy
Perica, K., Bieler, J. G., Schütz, C., Varela, J. C., Douglass, J., Skora, A. D., Chiu, Y., Oelke, M., Kinzler, K. W., Zhou, S., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b02829 · Cited by 147
Sleeping Beauty Transposon‐mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies
Huang, X., Guo, H., Kang, J., Choi, S., Zhou, T. C., Tammana, S., Lees, C. J., Li, Z.-Z., Milone, M. C., Levine, B. L., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300404 · Cited by 146
Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors
Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 145
Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 133
Bioengineering Thymus Organoids to Restore Thymic Function and Induce Donor-Specific Immune Tolerance to Allografts
Fan, Y., Tajima, A., Goh, S. K., Geng, X., Gualtierotti, G., Grupillo, M., Coppola, A., Bertera, S., Rudert, W. A., Banerjee, I., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.77 · Cited by 119
Designing natural and synthetic immune tissues
Gosselin, E. A., Eppler, H. B., Bromberg, J. S., & Jewell, C. M. (2018) · Nature Materials · doi:10.1038/s41563-018-0077-6 · Cited by 100
An injectable bone marrow–like scaffold enhances T cell immunity after hematopoietic stem cell transplantation
Shah, N. J., Mao, A. S., Shih, T., Kerr, M. D., Sharda, A., Raimondo, T. M., Weaver, J. C., Vrbanac, V. D., Déruaz, M., Tager, A. M., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0017-2 · Cited by 100
Identifying and managing the adverse effects of immune checkpoint blockade
Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 96
Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells
Xie, Y., Arik, H., Wei, L., Zheng, Y., Suh, H., Irvine, D. J., & Tang, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01556b · Cited by 91
Intratumoral rhIL‐12 administration in head and neck squamous cell carcinoma patients induces B cell activation
van Herpen, C. M. L., van der Voort, R., van der Laak, J. A. W. M., Klasen, I. S., de Graaf, A. O., van Kempen, L. C. L. T., de Vries, I. J. M., Boer, T. D., Dolstra, H., Torensma, R., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23756 · Cited by 90
Discovery and technology for human health
(2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0001 · Cited by 82
Multiscale engineering of immune cells and lymphoid organs
Kim, S., Shah, S. B., Graney, P. L., & Singh, A. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0100-9 · Cited by 79
Gel-Trapped Lymphorganogenic Chemokines Trigger Artificial Tertiary Lymphoid Organs and Mount Adaptive Immune Responses In Vivo
Kobayashi, Y., & Watanabe, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00316 · Cited by 72
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy
Amoozgar, Z., & Goldberg, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.007 · Cited by 69
Self-citation
What, Why, Where, and When: Bringing Timing to Immuno-Oncology
Rothschilds, A. M., & Wittrup, K. D. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.003 · Cited by 68
Phase I study of intratumoral application of recombinant human tumor necrosis factor
Pfreundschuh, M. G., Steinmetz, H. T., Tüschen, R., Schenk, V., Diehl, V., & Schaadt, M. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90034-5 · Cited by 66
Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation
Kosmides, A. K., Necochea, K., Hickey, J. W., & Schneck, J. P. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05284 · Cited by 66
Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies
Bartsch, H. H., Pfizenmaier, K., Schroeder, M. P., & Nagel, G. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90021-7 · Cited by 64
Delivery of 5′-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy
Jacobson, M. E., Wang-Bishop, L., Becker, K. W., & Wilson, J. T. (2018) · Biomaterials Science · doi:10.1039/c8bm01064a · Cited by 62
Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
Milhem, M. M., Gonzales, R., Medina, T. M., Kirkwood, J. M., Buchbinder, E. I., Mehmi, I., Niu, J., Shaheen, M. F., Weight, R. M., Margolin, K. A., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct144 · Cited by 56
Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments
Muraro, M. G., Muenst, S. E., Mele, V., Quagliata, L., Iezzi, G., Tzankov, A., Weber, W. P., Spagnoli, G. C., & Soysal, S. D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331798 · Cited by 44
Adsorption of Multimeric T Cell Antigens on Carbon Nanotubes: Effect on Protein Structure and Antigen‐Specific T Cell Stimulation
Fadel, T. R., Li, N., Shah, S., Look, M., Pfefferle, L. D., Haller, G. L., Justesen, S. F. L., Wilson, C. J., & Fahmy, T. M. (2012) · Small · doi:10.1002/smll.201201684 · Cited by 42
Engineering lymphocytes with RNAi
Ramishetti, S., & Peer, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.002 · Cited by 33
A sweeter approach to vaccine design
Wilson, J. T. (2019) · Science · doi:10.1126/science.aav9000 · Cited by 33
Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties
Hickey, J. W., Isser, A., Vicente, F. P., Warner, S. B., Mao, H., & Schneck, J. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.029 · Cited by 28
Time to deliver
Mash, R. J. (2006) · South African Family Practice · doi:10.1080/20786204.2006.10873431 · Cited by 26
Surface engineering for lymphocyte programming
Ben‐Akiva, E., Meyer, R. A., Wilson, D. R., & Green, J. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.005 · Cited by 22
Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models
Rothschilds, A. M., Tzeng, A., Mehta, N. K., Moynihan, K. D., Irvine, D. J., & Wittrup, K. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1558678 · Cited by 20
Artificial Antigen-Presenting Cells for Immunotherapies
Siefert, A. L., Fahmy, T. M., & Kim, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6646-2_21 · Cited by 10
Surgical wound immunotherapy
Liebers, R., & Jäger, D. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0328-3 · Cited by 5

Research works printed but not linked: 2

Luteijn, R. et al. SLC19A1 is a cyclic dinucleotide transporter. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/539767v1 (2019). · DOI
Nature Collection: Nobel Prize in Physiology or Medicine 2018, https://www.nature.com/collections/gqznlfngkz (2018).

Sorted by citations

Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R., & Zhou, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,288
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 691

See all 634

Authors: Goldberg, M. S.
Affiliations: Massachusetts Institute of Technology (US)
Corresponding author: Goldberg, Michael S.
ORCID: Goldberg, Michael S.
Venue: Nature reviews. Cancer
Publisher: Springer Science and Business Media LLC
Published: 2019-09-06
Volume: 19
Issue: 10
Pages: 587-602
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/s41568-019-0186-9
OpenAlex: W2972159813
Cited by: 628
References: 142
Citations by year: 2026: 44 · 2025: 67 · 2024: 81 · 2023: 98 · 2022: 114 · 2021: 122 · 2020: 92 · 2019: 10
FWCI: 8.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords: cancer immunotherapy, nanotechnology, nanoparticles, biomaterials, drug delivery, immune evasion, spatiotemporal control, pharmacokinetics, co-delivery, adoptive immunotherapy, tumor targeting, nanomedicine
MeSH terms: Animals, Biocompatible Materials, Humans, Immune System, Immunologic Factors, Immunotherapy, Leukocytes, Neoplasms, Nucleic Acids, T-Lymphocytes, Drug Delivery Systems, Adoptive Transfer, Nanomedicine, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Improving cancer immunotherapy through nanotechnology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks